排序方式: 共有54条查询结果,搜索用时 171 毫秒
31.
The health system burden of chronic disease care: an estimation of provider costs of selected chronic diseases in Uganda
下载免费PDF全文
![点击此处可从《Tropical medicine & international health : TM & IH》网站下载免费的PDF全文](/ch/ext_images/free.gif)
32.
Fermín Mearin Antonio M. Caballero Jordi Serra Carles Brotons Ana Tantiñà Esther Fort Francisco J. Martínez-Cerezo Antonia Perelló Gloria Sánchez-Antolín Enrique Rey Ramón Angós Musgo Ruth Berdier Blas Gómez-Rodríguez Pere Clavé Mónica García-Alonso Pere Torán-Monserrat Jan Tack 《Gastroenterologia y hepatologia》2019,42(3):141-149
33.
34.
Bonillo A 《Gaceta sanitaria / S.E.S.P.A.S》2012,26(3):231-235
Objectives
This study examines the accessing tests to Specialised Health Training for 2005 and 2006 calls. It aims to assess the quality of exams and explore candidates’ variables that allow predicting the final score.Methods
The Ministry of Health provided the 23,136 candidates’ answer from both calls, plus demographic variables and the normalised value of their student record.Results
Item's analysis is made from candidates’ answers for evaluating the test reliability. In addition, it's been calculated linear regression models for studying which variables allow predicting a candidate's final score.Conclusions
the accessing tests to Specialised Health Training have excellent psychometric quality. It would be improved by reducing the number of choices and eliminating some items more afterwards. Finally, Spanish students are the ones who achieved best adjusted mean score. 相似文献35.
Objective
To analyze the relationship between the degree of development of hospital cost systems (CS) implemented by the regional health services (RHS) and the variation in unit cost of hospitals in Spanish National Health Service (NHS) between 2010 and 2013 and to identify other explanatory factors of this variation.Methods
A database of NHS hospitals was constructed from exclusively public sources. Using a multilevel regression model, explaining factors of the variation in unit cost (cost per weighted unit of activity [WAU]) of a sample of 170 hospitals were analyzed.Results
The variables representative of the degree of development of CS are associated in a negative and significant way with the variation of the cost per WAU. It is observed that if a high-level development CS is used the cost variation per WAU would be reduced by close to 3.2%. There is also a negative and significant relationship between the variation in the cost per WAU and the variations in the percentage of high technology and the hospital occupancy rate. On the other hand, the variations in the average cost of personnel and in the number of workers per 100 beds are associated in a positive and significant way with the variation of the cost per WAU.Conclusion
In the period analysed, during which the main health expenditure adjustment was made, the control in hospital unit cost is associated not only with spending cuts but also with aspects related to their management, such as the implementation of more developed CS. 相似文献36.
José Antonio Pérez-Molina Esteban Martínez Antonio Javier Blasco José Ramón Arribas Pere Domingo José Antonio Iribarren Hernando Knobel Pablo Lázaro José López-Aldeguer Fernando Lozano Ana Mariño José M. Miró Santiago Moreno Eugenia Negredo Federico Pulido Rafael Rubio Jesús Santos Javier de la Torre Josep M. Gatell 《Enfermedades infecciosas y microbiología clínica》2019,37(3):151-159
Background
The GESIDA/National AIDS Plan expert panel recommended preferred regimens (PR), alternative regimens (AR) and other regimens (OR) for antiretroviral treatment (ART) as initial therapy in HIV-infected patients for 2018. The objective of this study was to evaluate the costs and the efficiency of initiating treatment with PR and AR.Methods
Economic assessment of costs and efficiency (cost-effectiveness) based on decision tree analyses. Effectiveness was defined as the probability of reporting a viral load <50 copies/mL at week 48, in an intention-to-treat analysis. Cost of initiating treatment with an ART regimen was defined as the costs of ART and its consequences (adverse effects, changes of ART regimen, and drug-resistance studies) over the first 48 weeks. The payer perspective (National Health System) was applied considering only differential direct costs: ART (official prices), management of adverse effects, studies of resistance, and HLA B*5701 testing. The setting was Spain and the costs correspond to those of 2018. A deterministic sensitivity analysis was conducted, building three scenarios for each regimen: base case, most favourable and least favourable.Results
In the base-case scenario, the cost of initiating treatment ranges from 6788 euros for TAF/FTC/RPV (AR) to 10,649 euros for TAF/FTC + RAL (PR). The effectiveness varies from 0.82 for TAF/FTC + DRV/r (AR) to 0.91 for TAF/FTC + DTG (PR). The efficiency, in terms of cost-effectiveness, ranges from 7814 to 12,412 euros per responder at 48 weeks, for ABC/3TC/DTG (PR) and TAF/FTC + RAL (PR), respectively.Conclusion
Considering ART official prices, the most efficient regimen was ABC/3TC/DTG (PR), followed by TAF/FTC/RPV (AR) and TAF/FTC/EVG/COBI (AR). 相似文献37.
Antonio Rivero José Antonio Pérez-Molina Antonio Javier Blasco José Ramón Arribas Víctor Asensi Manuel Crespo Pere Domingo José Antonio Iribarren Pablo Lázaro José López-Aldeguer Fernando Lozano Esteban Martínez Santiago Moreno Rosario Palacios Juan Antonio Pineda Federico Pulido Rafael Rubio Jesús Santos Josep M. Gatell 《Enfermedades infecciosas y microbiología clínica》2018,36(5):268-276
Introduction
GESIDA and the Spanish National AIDS Plan panel of experts have recommended preferred (PR), alternative (AR) and other regimens (OR) for antiretroviral therapy (ART) as initial therapy in HIV-infected patients for 2017. The objective of this study was to evaluate the costs and the efficiency of initiating treatment with PR and AR.Methods
Economic assessment of costs and efficiency (cost-efficacy) based on decision tree analyses. Efficacy was defined as the probability of reporting a viral load <50 copies/mL at week 48, in an intention-to-treat analysis. Cost of initiating treatment with an ART regimen was defined as the costs of ART and its consequences (adverse effects, changes of ART regimen and drug resistance studies) during the first 48 weeks. The payer perspective (National Health System) was applied considering only differential direct costs: ART (official prices), management of adverse effects, resistance studies and HLA B*5701 screening. The setting was Spain and the costs correspond to those of 2017. A deterministic sensitivity analysis was conducted, building three scenarios for each regimen: base case, most favourable and least favourable.Results
In the base case scenario, the cost of initiating treatment ranged from 6882 euro for TFV/FTC/RPV (AR) to 10,904 euros for TFV/FTC + RAL (PR). The efficacy varied from 0.82 for TFV/FTC + DRV/p (AR) to 0.92 for TAF/FTC/EVG/COBI (PR). The efficiency, in terms of cost-efficacy, ranged from 7923 to 12,765 euros per responder at 48 weeks, for ABC/3TC/DTG (PR) and TFV/FTC + RAL (PR), respectively.Conclusion
Considering ART official prices, the most efficient regimen was ABC/3TC/DTG (PR), followed by TFV/FTC/RPV (AR) and TAF/FTC/EVG/COBI (PR). 相似文献38.
J. Undabeitia S. Torres-Bayona N. Samprón M. Arrázola A. Bollar M. Armendariz P. Torres I. Ruiz M.C. Caballero L. Egaña A. Querejeta J. Villanua E. Pardo I. Etxegoien G. Liceaga M. Urtasun M. Michan J.I. Emparanza E. Úrculo 《Neurología (Barcelona, Spain)》2018,33(2):85-91
Introduction
Glioblastoma is the most common primary brain tumour. Despite advances in treatment, its prognosis remains dismal, with a mean survival time of about 14 months. Many articles have addressed direct costs, those associated with the diagnosis and treatment of the disease. Indirect costs, those associated with loss of productivity due to the disease, have seldom been described.Material and method
We conducted a retrospective study in patients diagnosed with glioblastoma at Hospital Universitario Donostia between January 1, 2010 and December 31, 2013. We collected demographics, data regarding the treatment received, and survival times. We calculated the indirect costs with the human capital approach, adjusting the mean salaries of comparable individuals by sex and age and obtaining mortality data for the general population from the Spanish National Statistics Institute. Past salaries were updated to 2015 euros according to the annual inflation rate and we applied a discount of 3.5% compounded yearly to future salaries.Results
We reviewed the records of 99 patients: 46 women (mean age 63.53) and 53 men (mean age 59.94); 29 patients underwent a biopsy and the remaining 70 underwent excisional surgery. Mean survival was 18.092 months for the whole series. The total indirect cost for the series was €11 080 762 (2015). Mean indirect cost per patient was €111 926 (2015).Discussion
Although glioblastoma is a relatively uncommon type of tumour, accounting for only 4% of all cancers, its poor prognosis and potential sequelae generate disproportionately large morbidity and mortality rates which translate to high indirect costs. Clinicians should be aware of the societal impact of glioblastoma and indirect costs should be taken into account when cost effectiveness studies are performed to better illustrate the overall consequences of this disease. 相似文献39.
《Archivos de bronconeumología》2021,57(7):464-470
BackgroundSaharan dust meets the Canary Islands at the beginning of its westward path across the North Atlantic, exceeding the European daily levels for PM10; for this reason, their two provincial capital cities, constitute optimal sites where to evaluate the health effects of this natural event.ObjectivesTo assess the short-term association between Saharan Dust Days (SDDs) and respiratory morbidity in the two capital cities.MethodsWe carried out a time-series analysis with daily emergency hospital admissions due to all respiratory system diseases, chronic obstructive pulmonary disease (COPD) and asthma between 2001 and 2005, assessing the independent effect of SDDs, defined according to the application of the methodology accepted by the European Environmental Office. We also examined accumulated effect, and some other specific SDDs’ features.ResultsWe found a short-term association between SDDs and the increase in admission risk for the three outcomes during concurrent SDDs, compared to non-SDDs, that spread from 0 to 5th day: 22.6% (95% confidence interval [CI], 10.4, 36.0) for all respiratory diseases and 29.9% (95%CI: 6.6, 58.4) for COPD in Santa Cruz de Tenerife, and 33.4% (95%CI: −2.1,82.0) for asthma in Las Palmas de Gran Canaria. We obtained a robust association when Saharan dust transported at low altitude, when SDDs belonged to long episodes (≥5 days), from the fifth SDD onwards and those SDDs with medium (50 < PM< 150) or high (≥150) PM10 levels.ConclusionsWe found evidence that SDDs carry a risk of emergency hospital admission from respiratory diseases in the Canary Islands. 相似文献
40.